BSE filing, NSE: APLLTD. Summary written from the filing by ALFA Finder's alert engine.
Alembic Pharmaceuticals Ltd: key numbers
- Share price
- ₹797.85
- Market cap
- ₹15,683 Cr
- Revenue (annual)
- ₹7,345 Cr
- Net profit (annual)
- ₹674.8 Cr
- P/E (TTM)
- 22.6×Sector 45.9×
- Promoter holding
- 69.87%+0.00% QoQ
- FII holding
- 4.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alembic Pharmaceuticals Ltd
All →Alembic Pharmaceuticals Board Meeting Date
Alembic Pharmaceuticals scheduled its board meeting for November 4, 2026, to consider unaudited Q1/H1 FY27 results. Trading window re-opens 48 hours post-declaration.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.
Alembic Pharmaceuticals Merger & Restructuring Worth ₹0.26 Cr
Alembic Pharmaceuticals' subsidiary, Alembic Global Holding SA, incorporated a new wholly-owned subsidiary, Alvesta Pharmaceuticals FZCO, in the UAE for Rs. 0.26 Crore.
- Value
- ₹0.26 Cr
Alembic Pharmaceuticals Merger & Restructuring Worth ₹0.23 Cr
Alembic Pharmaceuticals' wholly-owned subsidiary, Alembic Global Holding SA, incorporated a new step-down subsidiary, Alvesta Pharmaceuticals FZCO, in Dubai for AED 1 Lakh (approx. ₹0.23 Crore).
- Value
- ₹0.23 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Ciprofloxacin and Dexamethasone Otic Suspension USP. This drug is therapeutically equivalent to the reference product Ciprodex Otic Suspension.
Alembic Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern under SEBI Regulation 31(1)(b) for the period ended September 30, 2026.
Other legal & regulatory announcements
All →Lyka Labs Legal & Regulatory
Lyka Labs was fined ₹1.62 Lakhe by NSE for delayed FY 2025-26 Annual Report filing. The company has rectified the lapse and will pay within 15 days.
- Value
- ₹0.02 Cr
AstraZeneca Pharma India Legal & Regulatory
Delhi High Court directed NPPA to refrain from coercive steps on Rs.151.20 Crore alleged Symbicort Turbuhaler overcharging. Next hearing is January 11, 2027.
- Value
- ₹151.2 Cr
Jindal Poly Films Legal & Regulatory
Jindal Poly Films disclosed an NCLT petition under Sections 241-242 against Brookfield-linked investor Project Holdings Fourteen over oppression and mismanagement of subsidiary JPL Films. Related arbitration and Delhi High Court proceedings are pending, with financial impact not quantifiable.
Patel Chem Specialities Legal & Regulatory
BSE imposed a ₹0.01 Crore fine on Patel Chem Specialties for perceived LODR Reg 34 non-compliance. The company disputes the penalty, citing an inadvertent filing-year selection error.
- Value
- ₹0.01 Cr
Jyoti Legal & Regulatory
Jyoti Ltd received a rectification order from the Income Tax Department for AY 2020-21. The order levies an income tax demand of Rs.6.82 Crore including interest.
- Value
- ₹6.82 Cr
ICICI Bank Legal & Regulatory
ICICI Bank received an Order in Appeal confirming a GST penalty of Rs.6.95 lakh. The bank will appeal the order within prescribed timelines.
- Value
- ₹0.07 Cr